Nanobac Life Science, Inc.

Abstract accepted for presentation by the American Heart Association

Published in Cardiovascular Device Liability Week, September 19th, 2004

Nanobac Life Science, Inc. (OTCPK: NNBP), announced the abstract titled "Increased serum levels of Nanobacteria antibodies are associated with high coronary calcification score" has been accepted for presentation in an oral session at the American Heart Association (AHA) Scientific Sessions 2004.

The research was performed by Stephen Epstein, MD and Jianhui Zhu, PhD at the Washington Hospital Center, Washington, D.C.

"AHA is the leading cardiac organization and we are privileged to have a nanobacterial talk at a conference of this caliber," said John Stanton, Nanobac's CEO. "Having our NB2 test results discussed in an oral session shows growing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week

Source: Cardiovascular Device Liability Week (2004-09-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry